Its use brings a significant risk of arterial thrombosis, and therefore it should only be used in clinical trials or with patients with factor VIIe deficiency.
12.
The first report of its use in hemorrhage was in an Israeli soldier with uncontrollable bleeding in 1999 . Risks of its use include an increase in arterial thrombosis.
13.
With arterial thrombosis, blood vessel wall damage is required for thrombosis formation, as it initiates coagulation, but the majority of venous thrombi form without any injured epithelium.
14.
He also had a near survivor, after 24-hour kidney storage and delayed contralateral nephrectomy, in a dog that developed a late arterial thrombosis in the kidney.
15.
While it may help control bleeding, there is a risk of arterial thrombosis, and other than in those with factor VII deficiency, its use should be limited to clinical trials.
16.
In most cases, arterial thrombosis follows rupture of atheroma ( a fat-rich deposit in the blood vessel wall ), and is therefore referred to as " atherothrombosis ".
17.
It was being developed for secondary prevention of arterial thrombosis following Phase III clinical trials had not shown that sibrafiban was better than aspirin in preventing recurrent ischemic events in patients suffering from acute coronary syndrome.
18.
Thrombophilia screening in people with arterial thrombosis is generally regarded unrewarding and is generally discouraged, except possibly for unusually young patients ( especially when precipitated by coronary arterial bypass, fails because of rapid occlusion of the graft.
19.
According to a 2005 Medical Research Council randomized trial, the combination of hydroxyurea with aspirin is superior to the combination of anagrelide and aspirin for the initial management of ET . The hydroxyurea arm had a lower likelihood of myelofibrosis, arterial thrombosis, and bleeding, but it had a slightly higher rate of venous thrombosis.
